GDC-0623
/ Roche
- LARVOL DELTA
Home
Next
Prev
1 to 9
Of
9
Go to page
1
February 14, 2025
Myeloma-Developing Regimens Using Genomics (MyDRUG)
(clinicaltrials.gov)
- P1/2 | N=103 | Completed | Sponsor: Multiple Myeloma Research Consortium | Recruiting ➔ Completed | N=228 ➔ 103 | Trial completion date: Feb 2024 ➔ Dec 2024 | Trial primary completion date: Feb 2022 ➔ Dec 2024
Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • BRAF • SLC1A5
February 18, 2025
An in vitro pharmacogenomic approach reveals subtype-specific therapeutic vulnerabilities in atypical teratoid/rhabdoid tumors (AT/RT).
(PubMed, Pharmacol Res)
- "Subtype-dependent drug response profiles demonstrated sensitivity of AT/RT-SHH cell lines to B-cell lymphoma 2 (BCL2) and heat shock protein 90 (HSP90) inhibitors, and increased activity of microtubule inhibitors, kinesin spindle protein (KSP) inhibitors, and the eukaryotic translation initiation factor 4E (eIF4E) inhibitor briciclib in a subset of AT/RT-MYC cell lines. In summary, our in vitro pharmacogenomic approach revealed preclinical evidence of tumor type- and subtype-specific therapeutic vulnerabilities in AT/RT cell lines that may inform future in vivo and clinical evaluations of novel pharmacological strategies."
IO biomarker • Journal • Preclinical • B Cell Lymphoma • Brain Cancer • CNS Tumor • Embryonal Tumor • Glioma • Lymphoma • Malignant Glioma • Medulloblastoma • Oncology • Rhabdoid Tumor • Sarcoma • Solid Tumor • BCL2 • CDC37 • EIF4E • HSP90AA1 • SMARCA4 • SMARCB1
October 13, 2023
High in vitro and in vivo activity of BI-847325, a dual MEK/Aurora kinase inhibitor, in human solid and hematologic cancer models.
(PubMed, Cancer Res Commun)
- "BI-847325 showed a broader range of activity than the MEK inhibitor GDC-0623. In conclusion, dual MEK/Aurora kinase inhibition shows remarkable potential for treating multiple types of hematological and solid tumors. The combination with capecitabine was synergistic in colorectal, gastric, and mammary cancer."
Journal • Preclinical • Acute Lymphocytic Leukemia • Breast Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hematological Disorders • Hematological Malignancies • Hepatology • Leukemia • Melanoma • Oncology • Pancreatic Cancer • Solid Tumor • BRAF • MAP2K1 • NRAS
April 08, 2019
Myeloma-Developing Regimens Using Genomics (MyDRUG)
(clinicaltrials.gov)
- P1/2; N=228; Recruiting; Sponsor: Multiple Myeloma Research Consortium; Not yet recruiting ➔ Recruiting
Combination therapy • Enrollment open • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Oncology
January 04, 2022
MEK1/2 Inhibitor (GDC0623) Promotes Osteogenic Differentiation of Primary Osteoblasts Inhibited by IL-1β through the MEK-Erk1/2 and Jak/Stat3 Pathways.
(PubMed, Int J Endocrinol)
- "However, blocking of the MEK-Erk1/2 signaling pathway by GDC0623 treatment reversed these effects. Inhibition of Jak-Stat3 pathway by C188-9 downregulated the expression levels of MMP9 and MMP13, activated MEK-Erk1/2 pathway, and inhibited osteogenic differentiation."
Journal • CCND1 • IL1B • MMP13 • MMP9 • PCNA
February 22, 2014
A study evaluating the safety, tolerability, and pharmacokinetics of GDC-0623 in patients with locally advanced or metastatic solid tumors
(clinicaltrials.gov)
- P1, N=61; Sponsor: Genentech; Active, not recruiting; Primary trial completion date: Dec 2013 -> May 2014.
Trial primary completion • Oncology
April 03, 2020
Lignin-graft-PLGA drug-delivery system improves efficacy of MEK1/2 inhibitor in triple-negative breast cancer cell line.
(PubMed, Nanomedicine (Lond))
- "We demonstrated that GDC-0623 reversed epithelial-to-mesenchymal transition in TNBC. Our findings indicate that L-PLGA NPs are superior to PLGA NPs in delivering GDC-0623 to cancer cells for improved efficacy in vitro."
Journal • Preclinical
September 18, 2019
Novel lignin-conjugated PLGA drug delivery system improves efficacy of MEK1/2 inhibitor in triple negative breast cancer
(AACR-NCI-EORTC 2019)
- "L-PLGA-GDC was more effective at reversing EMT than free GDC-0623 and PLGA-GDC NPs. Our findings indicate that lignin conjugation improves characteristics of PLGA NPDDSs and improves efficacy of GDC-0623 in multiple assays."
Clinical
April 05, 2019
Strong anti-tumor activity of MEK inhibitor GDC-0623 and determination of predictive biomarkers
(AACR 2019)
- "Integrative analysis with significant genomic and transcriptomic parameters is currently ongoing to develop a molecular predictor of response to GDC-0623. Extending evaluation of the compound in vivo and validating predictors of response are needed to complete these preclinical investigations."
Biomarker
1 to 9
Of
9
Go to page
1